Compare Nomura Holdings Inc (NMR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs ResMed Inc. — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: Nomura Holdings Inc and ResMed Inc. are close in size by market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| NMR | RMD | |
|---|---|---|
Market Cap | $27.46B | $28.81B |
Sector | Financials | Health |
52-Week High | $10.04 | $293.73 |
52-Week Low | $6.39 | $182.82 |
Dividend Yield | 3.45% | 1.21% |
Enterprise Value | — | $27.99B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
